23:15 , Oct 26, 2018 |  BioCentury  |  Product Development

R&D merry-go-round

An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition...
23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies identified a GSDMD inhibitor that could help treat sepsis....
18:36 , Aug 23, 2018 |  BC Innovations  |  Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of...
17:16 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris. The candidate is a topical photoparticle therapy targeting the sebaceous...
18:27 , Mar 30, 2018 |  BC Week In Review  |  Company News

ICER issues final evidence report on CAR T therapies with policy recommendations

After the Institute for Clinical and Economic Review's California Technology Assessment Forum held a public meeting to discuss the comparative effectiveness and value of CAR T therapies, the institute released a final evidence report with...
00:43 , Mar 3, 2018 |  BioCentury  |  Finance

Rocky road

While a trio of buysiders who spoke with BioCentury believe sentiment toward Celgene Corp. will remain poor in the near term in the wake of a regulatory delay for ozanimod, they believe commercial success from...
00:06 , Mar 3, 2018 |  BC Extra  |  Politics & Policy

Senator questions pharmas on use of tax savings

Sen. Tina Smith (D-Minn.) sent letters to the CEOs of five large U.S. pharmas on Thursday questioning how they have been using their corporate tax savings since the passage of the Tax Cuts and Jobs...
20:46 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....
19:38 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an...